Iovance Biotherapeutics Inc (IOVA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.59B
Last updated: Nov 17, 2026 at 11:06 AM ET
Iovance Biotherapeutics Inc (IOVA) Earnings: Report Dates and Results
Iovance Biotherapeutics (IOVA) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Iovance Biotherapeutics reported EPS of -$0.05, above the -$0.09 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
IOVA has an expected report date of Feb 22, 2027.
IOVA Earnings Call
The latest IOVA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, IOVA beat 12, missed 22 and matched 6. Revenue for the quarter ended Sep 30, 2026 was $121.47M, up 80.1% from $67.45M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.05 | -$0.09 | -$0.10 - -$0.07 | +44.44% | Beat | N/A | 8 | 4 up, 0 down | Nov 5, 2026 | $121.47M |
| Jun 30, 2026 | -$0.11 | -$0.17 | N/A | +35.29% | Beat | N/A | 7 | N/A | Aug 6, 2026 | $99.31M |
| Mar 31, 2026 | -$0.19 | -$0.15 | -$0.22 - -$0.08 | -23.78% | Miss | N/A | 8 | 0 up, 2 down | May 7, 2026 | $71.43M |
| Dec 31, 2025 | -$0.18 | -$0.18 | -$0.21 - -$0.14 | 0.00% | In line | N/A | 8 | 0 up, 1 down | Feb 24, 2026 | $86.77M |
| Sep 30, 2025 | -$0.25 | -$0.26 | -$0.30 - -$0.22 | +3.85% | Beat | N/A | 9 | 5 up, 2 down | Nov 6, 2025 | $67.45M |
| Jun 30, 2025 | -$0.33 | -$0.29 | -$0.34 - -$0.22 | -13.79% | Miss | N/A | 9 | 0 up, 8 down | Aug 7, 2025 | $59.95M |
| Mar 31, 2025 | -$0.36 | -$0.24 | -$0.26 - -$0.18 | -50.00% | Miss | N/A | 10 | 1 up, 1 down | May 8, 2025 | $49.32M |
| Dec 31, 2024 | -$0.26 | -$0.27 | -$0.36 - -$0.23 | +2.84% | Beat | N/A | 10 | 2 up, 4 down | Feb 27, 2025 | $73.69M |
| Sep 30, 2024 | -$0.28 | -$0.30 | -$0.35 - -$0.25 | +6.67% | Beat | N/A | 13 | 0 up, 0 down | Nov 7, 2024 | $58.55M |
| Jun 30, 2024 | -$0.34 | -$0.35 | -$0.44 - -$0.29 | +2.86% | Beat | N/A | 12 | 1 up, 2 down | Aug 8, 2024 | $31.11M |
| Mar 31, 2024 | -$0.42 | -$0.42 | -$0.50 - -$0.32 | 0.00% | In line | N/A | 12 | 0 up, 0 down | May 9, 2024 | $715000 |
| Dec 31, 2023 | -$0.45 | -$0.43 | -$0.48 - -$0.34 | -4.65% | Miss | N/A | 13 | 3 up, 2 down | Feb 28, 2024 | $482000 |
| Sep 30, 2023 | -$0.46 | -$0.46 | -$0.52 - -$0.41 | 0.00% | In line | N/A | 13 | 0 up, 0 down | Nov 7, 2023 | $469000 |
| Jun 30, 2023 | -$0.47 | -$0.79 | -$1.72 - -$0.41 | +40.51% | Beat | N/A | 13 | 0 up, 0 down | Aug 8, 2023 | $238000 |
| Mar 31, 2023 | -$0.50 | -$0.73 | -$1.52 - -$0.49 | +31.51% | Beat | N/A | 14 | 0 up, 0 down | May 9, 2023 | N/A |
| Dec 31, 2022 | -$0.64 | -$0.64 | -$0.70 - -$0.53 | 0.00% | In line | N/A | 14 | 1 up, 0 down | Feb 28, 2023 | N/A |
| Sep 30, 2022 | -$0.63 | -$0.64 | -$0.70 - -$0.56 | +1.56% | Beat | N/A | 14 | 0 up, 0 down | Nov 3, 2022 | N/A |
| Jun 30, 2022 | -$0.63 | -$0.61 | -$0.70 - -$0.53 | -3.28% | Miss | N/A | 14 | 1 up, 0 down | Aug 4, 2022 | N/A |
| Mar 31, 2022 | -$0.58 | -$0.63 | -$0.73 - -$0.57 | +7.94% | Beat | N/A | 14 | 0 up, 0 down | May 5, 2022 | N/A |
| Dec 31, 2021 | -$0.63 | -$0.56 | -$0.58 - -$0.53 | -12.50% | Miss | N/A | 14 | N/A | Feb 24, 2022 | N/A |
| Sep 30, 2021 | -$0.55 | -$0.53 | -$0.58 - -$0.48 | -3.77% | Miss | N/A | 14 | 4 up, 0 down | Nov 4, 2021 | N/A |
| Jun 30, 2021 | -$0.53 | -$0.51 | -$0.57 - -$0.46 | -3.92% | Miss | N/A | 14 | N/A | Aug 5, 2021 | N/A |
| Mar 31, 2021 | -$0.51 | -$0.49 | -$0.60 - -$0.44 | -4.08% | Miss | N/A | 14 | N/A | May 6, 2021 | N/A |
| Dec 31, 2020 | -$0.47 | -$0.44 | -$0.50 - -$0.38 | -6.82% | Miss | N/A | 12 | N/A | Feb 25, 2021 | N/A |
| Sep 30, 2020 | -$0.40 | -$0.46 | -$0.54 - -$0.39 | +13.04% | Beat | N/A | 12 | N/A | Nov 5, 2020 | N/A |
| Jun 30, 2020 | -$0.47 | -$0.52 | -$0.56 - -$0.47 | +9.62% | Beat | N/A | 12 | N/A | Aug 6, 2020 | N/A |
| Mar 31, 2020 | -$0.55 | -$0.51 | -$0.65 - -$0.42 | -7.84% | Miss | N/A | 12 | N/A | May 5, 2020 | N/A |
| Dec 31, 2019 | -$0.50 | -$0.42 | -$0.45 - -$0.40 | -19.05% | Miss | N/A | 10 | N/A | Feb 25, 2020 | N/A |
| Sep 30, 2019 | -$0.40 | -$0.39 | -$0.43 - -$0.37 | -2.56% | Miss | N/A | 9 | N/A | Nov 4, 2019 | N/A |
| Jun 30, 2019 | -$0.38 | -$0.29 | -$0.34 - -$0.18 | -31.03% | Miss | N/A | 9 | N/A | Aug 1, 2019 | N/A |
| Mar 31, 2019 | -$0.30 | -$0.29 | -$0.37 - -$0.18 | -3.45% | Miss | N/A | 9 | N/A | May 7, 2019 | N/A |
| Dec 31, 2018 | -$0.27 | -$0.26 | -$0.33 - -$0.22 | -3.85% | Miss | N/A | 7 | N/A | Feb 27, 2019 | N/A |
| Sep 30, 2018 | -$0.36 | -$0.33 | -$0.36 - -$0.30 | -9.09% | Miss | N/A | 7 | N/A | Nov 6, 2018 | N/A |
| Jun 30, 2018 | -$0.34 | -$0.32 | -$0.34 - -$0.29 | -6.25% | Miss | N/A | 7 | N/A | Aug 6, 2018 | N/A |
| Mar 31, 2018 | -$0.31 | -$0.29 | -$0.33 - -$0.23 | -6.90% | Miss | N/A | 6 | N/A | May 10, 2018 | N/A |
| Dec 31, 2017 | -$0.32 | -$0.32 | -$0.34 - -$0.29 | 0.00% | In line | N/A | 7 | N/A | Mar 12, 2018 | N/A |
| Sep 30, 2017 | -$0.35 | -$0.29 | N/A | -20.69% | Miss | N/A | N/A | N/A | Oct 31, 2017 | N/A |
| Jun 30, 2017 | -$0.37 | -$0.28 | N/A | -32.14% | Miss | N/A | N/A | N/A | Aug 1, 2017 | N/A |
| Mar 31, 2017 | -$0.28 | -$0.27 | N/A | -3.70% | Miss | N/A | N/A | N/A | May 1, 2017 | N/A |
| Dec 31, 2016 | -$0.25 | -$0.25 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 7, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.12, after -$1.30 the year before. It was -$0.79 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.12 | N/A |
| Dec 31, 2024 | -$1.30 | N/A |
| Dec 31, 2023 | -$1.88 | N/A |
| Dec 31, 2022 | -$2.48 | N/A |
| Dec 31, 2021 | -$2.22 | N/A |
| Dec 31, 2020 | -$1.89 | N/A |
| Dec 31, 2019 | -$1.58 | N/A |
| Dec 31, 2018 | -$1.28 | N/A |
| Dec 31, 2017 | -$1.32 | N/A |
| Dec 31, 2016 | -$0.79 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,700 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,696 | 12 | |
| 2026Q2 | Jun 30, 2026 | 5,592 | 11 | |
| 2026Q1 | Mar 31, 2026 | 5,037 | 12 | |
| 2025Q4 | Dec 31, 2025 | 6,229 | 19 | |
| 2025Q3 | Sep 30, 2025 | 5,478 | 16 | |
| 2025Q2 | Jun 30, 2025 | 5,472 | 15 | |
| 2025Q1 | Mar 31, 2025 | 7,208 | 17 | |
| 2024Q4 | Dec 31, 2024 | 6,937 | 17 |
2026Q3 Earnings Call
Opening remarks
Jen Saunders Senior Director, Investor Relations and Corporate Communications Thank you, Daniel. Good morning, and welcome to the Iovance webcast to discuss our third quarter 2026 financial results, business achievements, and corporate updates. This morning, we issued a press release that is available on our corporate website at iovance.com. This conference call will include forward-looking statements regarding Iovance's goals, business focus, business plans and transactions, revenue and revenue guidance, commercial activities, clinical trials and results, regulatory approvals, submissions, feedback and guidance, plans and strategies, research and preclinical activities, potential future applications of our technologies, manufacturing capabilities, payer interactions, licenses and collaborations, cash position, and future updates. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time to time in our SEC filings. Our results may differ materially from those projected during today's call. We undertake no obligation to publicly update any forward-looking statements. I will now turn the call over to Dr. Fred Vogt, Interim CEO and President.
Fred Vogt Interim CEO and President Thank you, Jen. Good morning, everyone. Our third quarter delivered outstanding record-setting results for Iovance, with our highest ever revenue and margin and strong financial performance across the board. Total revenue of about $122 million surged 80% over the prior year. U.S. AMTAGVI revenue increased 77% over the prior year and crossed $100 million in a single quarter for the first time. We also passed an important landmark this quarter, with more than 1,000 commercial AMTAGVI patients now infused in the U.S. since launch. Based on this strong performance, we remain on track to achieve our full-year revenue guidance of $410 million-$420 million. Our authorized treatment center, or ATC, network continues to expand rapidly, and we fully expect to reach 110 or more authorized treatment centers by year-end. Third quarter margin of about 60% also set a new all-time high for the second consecutive quarter, and we expect it to expand further over time. Our cash runway is now expected to fund operations well into 2029. This strong performance reflects the financial health of Iovance and the strong platform that we can build upon for upcoming launches. The third quarter and recent updates also reflect major progress across our TIL platform and pipeline programs. In metastatic non-small cell lung cancer, lifileucel continues to demonstrate a potentially best-in-class clinical profile. Earlier this year, the FDA granted fast-track designation based on the strength of our data and the high unmet need. Last week, we reported positive updated results from our registrational IOV-LUN-202 trial that included 69 patients with previously treated non-squamous metastatic non-small cell lung cancer. The objective response rate, or ORR, by RECIST 1.1 was 24.6%, consistent with our prior results in 39 patients.
Frequently Asked Questions About IOVA
When is Iovance Biotherapeutics's next earnings date?
Iovance Biotherapeutics's next earnings report is expected for Feb 22, 2027.
Did IOVA beat earnings estimates last quarter?
Yes. Iovance Biotherapeutics reported EPS of -$0.05 for the quarter ended Sep 30, 2026, above the -$0.09 estimate, a 44.44% surprise.
What EPS do analysts expect from IOVA next quarter?
The consensus EPS estimate for Iovance Biotherapeutics for the quarter ending Dec 31, 2026 is -$0.08 from 12 analysts, with estimates from -$0.12 to -$0.04.
How often does IOVA beat earnings estimates?
Iovance Biotherapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -0.14%.
IOVA pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts